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A stability indicating HPLC method to determine diltiazem hydrochloride (DTZ) in tablets and 
compounded capsules was developed and validated according to Brazilian and the International 
Conference on Harmonization (ICH) guidelines. The separation was carried out on a Purospher Star® C18 
(150 x 4.6 mm i.d., 5 µm particle size, Merck Millipore) analytical column. The mobile phase consisted 
of a 0.05% (v/v) trifluoroacetic acid aqueous solution and a 0.05% trifluoroacetic acid methanolic solution 
(44:56, v/v). The flow rate was 1.0 mL.min-1 with a run time of 14 minutes. The detection of DTZ and 
degradation products (DP) was performed at 240 nm, using a diode array detector. The method proved 
to be linear, precise, accurate, selective, and robust, and was adequate for stability studies and routine 
quality control analyses of DTZ in tablets and compounded capsules.
Keywords: Diltiazem hydrochloride/compounded capsules. Diltiazem hydrochloride/tablets. High 
performance liquid chromatography /method validation. Stability indicating method.
INTRODUCTION
Diltiazem hydrochloride (DTZ), chemically known 
as 1,5-benzothiazepin-4(5H )-one, 3-(acetyloxy)-5-[2-
(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, 
monohydrochloride (Figure 1), molecular mass of 450.98 
g.mol-1, is commonly prescribed to treat hypertension and 
angina pectoris, exerting its effects by promoting arterial 
smooth muscle relaxation, a reduction in coronary vascular 
resistance, and an increase in blood flow to the coronary 
arteries (Brunton, Lazo, Parker, 2006).
Diltiazem is almost completely absorbed by the 
gastrointestinal tract and undergoes extensive first-pass 
hepatic metabolism. The maximum plasma concentration 
is reached about three to four hours after the administration 
of diltiazem tablets (Sweetman, 2009).
DTZ is commercially available in tablet, extended-
release capsule, extended-release tablet, suspension, oral 
solution, and intravenous injection dosage forms (AHFS, 
2004; USP, 2014). Furthermore, diltiazem can also be 
compounded in specific pharmacies. These compounding 
pharmacies usually produce DTZ in immediate-release 
capsule dosage form. In addition, in Brazil, compounding 
pharmacies are allowed to produce capsules that contain 
the same strength of commercial products.
To date, there are no pharmacopeial monographs for 
the analysis of diltiazem in compounded capsules, only for 
FIGURE 1 - Chemical structure of diltiazem hydrochloride 
(DTZ).
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raw material and tablet, extended-release tablet, extended-
release capsule, suspension, and oral solution dosage 
forms (USP, 2014; British Pharmacopoeia, 2013). There 
are several HPLC methods reported to determine diltiazem 
in pharmaceutical dosage forms, but only one is a stability 
indicating method that is able to determine diltiazem in 
the presence of its degradation products (Chatpalliwar, 
Porwal, Upmanyu, 2012). However, the analytical 
method has a high running time and is incompatible for 
coupling with a mass detector. Furthermore, there are no 
stability indicating methods for diltiazem determination 
in compounded capsules.
This study aimed to develop and validate a simple 
and selective HPLC method to quantify diltiazem in 
tablets and compounded capsules containing 30 mg DTZ 
in the presence of its hydrolytic and oxidative degradation 
products.
MATERIAL AND METHODS
Chemical, reagents, and material
The diltiazem hydrochloride reference standard 
(100.2% purity) was obtained from the Brazilian 
Pharmacopoeia (Brasília, DF, Brazil), DTZ capsules, 
and placebo capsules were obtained from a compounding 
pharmacy located in Belo Horizonte, MG, Brazil, while 
DTZ reference drug and generic tablets were obtained 
from a drugstore located in Belo Horizonte, MG, Brazil. 
Ultrapure water was obtained from a Millipore system 
(Bedford, MA, USA). Methanol (HPLC grade) and sodium 
hydroxide (analytical grade) were purchased from J. T. 
Baker (Phillipsburg, NJ, USA); trifluoroacetic acid (HPLC 
grade) was purchased from Tedia (Fairfield, OH, USA); 
glacial acetic acid and anhydrous formic acid (analytical 
grade) were purchased from Sigma-Aldrich (St Louis, MO, 
USA); and ammonium acetate, hydrogen peroxide, and 
hydrochloric acid (analytical grade) were purchased from 
Synth (Diadema, SP, Brazil). Quantitative filter paper was 
purchased from J. Prolab (São José dos Pinhais, PR, Brazil). 
Instrumentation
The HPLC-DAD analyses were carried out in a 
Thermo Finnigan Surveyor System (San Jose, CA, USA), 
comprised of a quaternary pump, degasser, autosampler, 
column oven, and photodiode array detector. The 
chromatographic separation was performed on a Merck 
Millipore Purospher Star® C18 column (150 x 4.6 mm i.d.; 
5 µm particle size) maintained at 30ºC. UV detection was 
performed at 240 nm. UV spectra from 200 to 400 nm 
were recorded online for peak identification. The injection 
volume was 20 µL. The optimized mobile phase was a 
mixture of a 0.05% (v/v) trifluoroacetic acid aqueous 
solution and a 0.05% (v/v) trifluoroacetic acid methanolic 
solution (44:56, v/v) at a flow rate of 1.0 mL.min-1. 
To determine k (retention factor) and t0 (column dead 
time) a 0.1% (w/v) uracil solution was injected onto the 
chromatograph.
The HPLC-ESI-MS/MS analyses were carried out 
in a Waters system (New Castle, DE, USA), comprised of 
a 1525 µ binary pump, a 2777 sample manager, a TCM/
CHM column oven, and a Quattro LC triple quadrupole 
mass spectrometer, equipped with an electrospray ion 
source. Mass Lynx version 4.1 software was used for data 
acquisition and analysis. The separation was performed on 
the same column that was employed in the HPLC-DAD 
method development.
Preparation of solutions
Standard solutions
Approximately 15 mg of diltiazem hydrochloride 
were accurately weighed and transferred to a 100 mL 
volumetric flask, followed by the addition of 30 mL of 
methanol. The flask was sonicated for 10 minutes and 
filled to the mark with water. An aliquot of 10 mL of the 
solution was transferred to a 50 mL volumetric flask. The 
flask was filled to the mark with water. The final solution, 
with a concentration of 30 µg.mL-1, was filtered using a 
PVDF syringe filter with a 0.45 µm pore size.
Capsule samples
The average content weight of 20 capsules 
containing 30 mg of DTZ was determined and the 
powder was further homogenized. An amount of 
powder equivalent to 30 mg of DTZ was transferred 
to a 100 mL volumetric flask, followed by the addition 
of 50 mL of methanol. The flask was sonicated for 
10 minutes and was filled to the mark with water. The 
solution was filtered using filter paper. An aliquot 
of 5 mL of the solution was transferred to a 50 mL 
volumetric flask. The flask was then filled to the mark 
with water. The final solution, with a concentration of 
30 µg.mL-1, was filtered using a PVDF syringe filter with 
a 0.45 µm pore size.
Tablet samples
The average weight of 20 tablets containing 30 mg 
of DTZ was determined. The tablets were crushed, and the 
powder was further homogenized. An amount of powder 
equivalent to 30 mg of DTZ was transferred to a 100 mL 
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volumetric flask, followed by the addition of 50 mL of 
methanol. The flask was sonicated for 10 minutes and was 
filled to the mark with water. The solution was filtered 
using filter paper. An aliquot of 5 mL of the solution was 
transferred to a 50 mL volumetric flask. The flask was 
filled to the mark with water. The final solution, with a 
concentration of 30 µg.mL-1, was filtered using a PVDF 
syringe filter with a 0.45 µm pore size.
Method validation
The method was validated according to the Brazilian 
Guideline RE N° 899/2003 (ANVISA, 2003), International 
Conference on Harmonization (ICH) Guidance for 
industry Q1A R2 Stability testing of new drug substances 
and products (ICH, 2003) and ICH Guidance for Industry 
Q2 (R1) Validation of analytical procedures: text and 
methodology (ICH, 2005).
Selectivity
• Intrinsic stability evaluation
Stress tests were performed on DTZ to evaluate its 
stability in hydrolytic (acid, alkaline, and neutral) and 
oxidative conditions. The stress tests were conducted 
similarly to those described by Nogueira et al. (2011) for 
mefloquine hydrochloride and as recommended by the 
ICH (ICH, 2003).
A DTZ stock solution (0.2 mg.mL-1) was prepared 
in methanol. Aliquots of 5 mL of this solution were 
transferred to four test tubes. Five mL of hydrochloric 
acid 0.2 M, 100 µL of sodium hydroxide 0.02 M (and 
4.9 mL of water), 5 mL of water and 5 mL of hydrogen 
peroxide 6% (v/v) were added to each tube, separately. 
The total volume of the tubes was 10 mL, which was 
maintained in a water bath at 50oC for 21h. At 0, 1, 2, 
3, 6, and 21h, aliquots of 1 mL of the solutions were 
drawn, and 20 µl were injected onto the chromatograph. 
The chromatographic conditions were adjusted in order 
to provide an adequate separation between DTZ and its 
degradants.
• Selectivity in relation to the formulation excipients
Capsules
A sample solution was prepared with the placebo 
capsules (containing microcrystalline cellulose 
and lactose monohydrate only), injected onto the 
chromatograph, and monitored for 30 minutes to evaluate 
interfering peaks in the diltiazem retention time and 
possible late eluting peaks. In addition, three solutions 
containing DTZ, capsule excipients, and diluent, as well 
as three solutions containing only DTZ and diluent, 
were prepared. The solutions were injected onto the 
chromatograph, the content of DTZ was determined 
and compared using a Student’s t test. The statistical 
significance was set at 5%.
Tablets
Mixtures of excipients used in the manufacture 
of the tablets were prepared. The composition of the 
formulations was estimated based on information on the 
drugs labels and the percentages usually employed to 
produce tablets (Rowe, Sheskey, Quinn, 2009). A sample 
solution was prepared with the mixture of excipients and 
injected onto the chromatograph and monitored for 30 
minutes to evaluate interfering peaks in the diltiazem 
retention time and possible late eluting peaks. In addition, 
three solutions containing DTZ, the mixture of excipients, 
and the diluent, as well as and three solutions containing 
only DTZ and diluent, were prepared. The solutions were 
injected onto the chromatograph, the DTZ content was 
determined and compared using a Student’s t test. The 
statistical significance was set at 5%.
Linearity
The linearity of the method was evaluated at five 
concentration levels, between 50% and 150% of the 
working concentration (30 µg.mL-1). A standard stock 
solution containing 150 µg.mL-1 of DTZ in methanol 
was prepared. Aliquots of this solution were diluted 
in the mobile phase for five different concentrations, 
corresponding to 50%, 75%, 100%, 125%, and 150% of 
the working concentration. The solutions were randomly 
prepared and randomly injected onto the chromatograph.
The assumptions for the employment of the ordinary 
least squares method were evaluated according to Souza 
and Junqueira (2005): the verification of the outliers (the 
Jackknife residuals test), the normality (Ryan Joiner´s 
test), the homoscedasticity (modified Levene´s test), and 
the independence of the residuals (Durbin-Watson test). 
The regression significance and the linearity deviation 
were evaluated by analysis of variance (ANOVA). The 
statistical significance was set at 5%.
Accuracy, Intraday, and Interday Precision 
Accuracy and precision were evaluated in a placebo 
contamination procedure. The DTZ working standard was 
added to the capsule matrix and to the mixture of excipients 
of the tablets to obtain three concentration levels: 50%, 
100% and 150% of the working concentration. Twelve 
solutions were prepared for each concentration level, and 
the assay was performed on two separate days, separated 
by a one-week interval.
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The recovery results were analyzed for the presence 
of outliers, employing the Grubbs method, in a similar 
manner to that described by Gomes and Souza (2010). 
Precision was evaluated using the relative standard 
deviation of the sample assays.
Robustness and System Suitability
Method robustness was assessed by determining the 
DTZ content in six tablet and capsule sample solutions. 
Samples were assayed under nominal conditions and 
by the variation of the following analytical parameters: 
methanol concentration in the mobile phase (54-58%), 
flow rate (0.9-1.1 mL.min-1), and oven temperature 
(25-35 oC). Obtained data were submitted to statistical 
analyses (ANOVA test). The assays were performed 
in sextuplicate. The retention factor, tailing factor, and 
theoretical plate number were evaluated for five injections 
of the standard solution in each condition to set the system 
suitability parameters. The criteria established by the FDA 
(1994) for the system suitability parameters were used to 
judge the results.
Detection and quantitation limit 
Detection and quantitation limits were estimated 
using the analytical curve for DTZ and later confirmed by 
injecting solutions at the estimated concentrations onto the 
chromatograph. The solutions were diluted and injected. 
The detection limit and quantitation limit were set at a 
signal/noise ratio of 3 and 10, respectively.
HPLC-ESI-MS/MS analyses
The LC separation was performed on a Purospher 
Star® C18 column (150 x 4.6 mm i.d.; 5 µm particle size). 
The oven temperature was maintained at 30°C. The mobile 
phase consisted of (A) 0.1% formic acid in methanol and 
(B) 0.1% formic acid in water, and delivered at a flow rate 
of 1 mL.min-1.
Mass spectrometric detection was performed using 
an electrospray ion source in the positive ionization 
mode. Nitrogen was used as both the nebulizing and the 
desolvation gas. The ion source parameters were: capillary 
2.75 kV, extractor 4 V, RF lens 0.4 V, source temperature 
of 100°C, desolvation temperature of 350 °C, and a DTZ 
cone of 35 V. The multiplier was set at 650 V. 
The total ion current chromatograms (TIC) of 
diltiazem solutions subjected to degradation were acquired 
using a full-scan MS mode. To identify degradation 
products, mass spectra were obtained for each observed 
chromatographic peak, in the range of 0 to 500 Da.
RESULTS AND DISCUSSION
Intrinsic stability evaluation
Three degradation products were obtained in the 
experiments which employed acid, neutral, and alkaline 
reagents. These degradation products were initially named 
DP1, DP2, and DP3, respectively. Three degradation 
FIGURE 2 - Chromatograms of the sample solution obtained from HPLC-DAD experiments after degradation by acid hydrolysis, 
aqueous hydrolysis, alkaline hydrolysis and oxidation, where one can see the DTZ peaks (k=4.46) and the degradation products 1 
(k=2.47), 2 (k=2.93), 3 (k=2.60), 4 (k=0.61), 5 (k=2.71), and 6 (k=5.75).
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products, named DP4, DP5, and DP6, were obtained in 
the oxidative experiment. The chromatograms of the 
degradation experiments are shown in Figure 2.
The degradation products DP1, DP2, DP3, and 
DP5 presented similar retention factors and UV spectra. 
Moreover, the UV spectra of the degradation products 
were similar to the diltiazem spectrum. HPLC-ESI-MS/
MS was employed to identify the degradation products.
The HPLC-ESI-MS/MS analyses
The mass spectrum of a standard DTZ solution 
(500 ng.mL-1) was recorded using direct injection onto 
the mass spectrometer. The protonated molecule [M+H]+ 
presented an m/z of 415. The solutions subjected to forced 
degradation were analyzed using HPLC-ESI-MS/MS 
and the mass spectra of the degradation products were 
recorded. The degradation products DP1, DP2, DP3, and 
DP5 presented a protonated molecule [M+H]+ of 373, 
which suggests that they are the same compound, since 
their retention factors were also similar.
It can be observed, in diltiazem hydrochloride 
chemical structure, that there is a group which can suffer 
hydrolysis – the ester carbonyl. Moreover, the loss of this 
group and the addition of one hydrogen atom results in 
a molecule with a molecular mass of 372 g.mol-1, which 
agrees with the m/z obtained for DP1, DP2, DP3, and DP5. 
British Pharmacopoeia describes a DTZ impurity (Impurity 
F) as having a molecular mass of 372 g.mol-1 and one less 
carboxyl group than diltiazem (British Pharmacopoeia, 
2013). These findings made us believe that the main 
degradation product of diltiazem is the impurity F. The 
degradation scheme, as well as the possible chemical 
structure of the degradation products DP1, DP2, DP3, and 
DP5, are shown in Figure 3.
The other degradation products obtained in the 
oxidation experiment (DP4 and DP6) were not detected 
in the HPLC-ESI-MS/MS analysis, probably due to their 
low concentration.
Among the many analytical methods available in 
the literature, only one is a stability indicating method, 
in other words, it is capable of assaying DTZ in the 
presence of its degradation products (Chatpalliwar, 
Porwal, Upmanyu, 2012). However, this method 
presents a run time of 80 minutes. The analytical method 
developed in our work employed real samples and was 
capable of separating DTZ from its degradation products 
within a significantly lower run time (14 minutes). 
Furthermore, its mobile phase is compatible with tandem 
mass detection, which can be useful in further studies 
conducted with DTZ.
Analytical method validation
Selectivity
No interfering peaks were observed in the DTZ 
retention time and no late eluting peaks were observed in 
the runs performed with placebo solutions. In addition, no 
statistical difference (p = 0.21 for compounded capsules, 
p=0.86 for reference drug, and p = 0.66 for generic drug, 
being the last two tablet formulations) was found between 
the sample solutions with and without added excipients, 
proving that the latter does not interfere in the quantitative 
analysis of diltiazem.
The intrinsic stability evaluation demonstrated that 
the analytical method is capable of determining diltiazem 
in the presence of its degradation products, proving to be 
selective to determine diltiazem in compounded capsules 
and tablets.
Linearity
After having performed the statistical tests, it was 
FIGURE 3 - Degradation scheme of DTZ and the possible chemical structure of the degradation products DP1, DP2, DP3, and DP5.
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observed that the data is in agreement with all of the 
least squares method assumptions. Three outliers were 
excluded, and this number is in accordance with the 
rule of excluding a maximum of 2/9 of the data (Souza, 
Junqueira, 2005).
The residues presented random distribution, the 
regression was statistically significant (p<0.01), and no 
lack of adjustment to the linear model was observed (p = 
0.32). The correlation coefficient was higher than 0.99, as 
required (ANVISA, 2003; FDA, 1994). The regression 
analysis data are shown in Table I.
Accuracy, Intraday, and Interday Precision
The mean recovery for the concentration levels of 
50%, 100%, and 150% after the removal of outliers are 
shown in Table II. Mean recoveries are within the 98% 
to 102% range, which is in agreement with the literature 
(Green, 1996).
With respect to the method precision, the data 
followed normal distribution and were homoscedastic. The 
relative standard deviation for the intraday and interday 
precision are also described in Table II. 
The relative standard deviation values were lower 
than 5%, as established by Brazilian law (ANVISA, 2003). 
It is suggested in the literature that the RSD values for 
intraday precision should be below 2% (Green, 1996). 
The RSD values obtained in the interday precision were 
also close to 2%.
Robustness and system suitability
Statistical analysis showed no significant difference 
(p = 0.28) between results obtained employing the 
analytical conditions established for the method and those 
obtained in the experiments in which variations of some 
parameters were introduced. Thus, the method proved to 
be robust for changes within the mobile phase flow rate 
from 0.9 to 1.1 mL.min-1, methanol proportion from 54% 
to 58%, and column temperature from 25 ºC to 35 ºC.
The parameters of system suitability, such as the 
retention factor, the number of theoretical plates, the 
asymmetry factor, and repeatability, were considered 
adequate at all variations in chromatographic parameters, 
as shown in Table III, confirming that the analytical 
method is suitable to determine DTZ within the conditions 
for which it was considered robust. 
Detection and quantitation limit
Employing the signal/noise ratio method, the 
detection and quantitation limits were lower than 0.15 
µg.mL-1 and 0.75 µg.mL-1, respectively, for an injection 
volume of 20 µL.
CONCLUSIONS
The developed method proved to be selective, 
linear, precise, accurate, and robust. DTZ was separated 
from its degradation products with an adequate run time 
of 14 minutes, and the method is compatible for coupling 
with a mass detector. The method proved to be a simple 
TABLE I - Overview of the linearity data for diltiazem
Regression Parameter Result
r2 0.9995
Slope ± SE 307.46 ± 2.12
Intercept ± SE -473.47 ± 68.29
Concentration range (µg.mL-1) 15.0 - 45.0
Number of points 5
TABLE II - Mean recovery to determine the accuracy and relative standard deviation (RSD) for intraday and interday precision of 
the analytical method (n=12 for each concentration level)
Concentration level Mean recovery (%) Intraday precision RSD (%)
Interday precision 
RSD (%)
Capsules
50% 98.3 1.5 2.4
100% 99.6 0.8 1.0
150% 100.8 0.8 1.0
Tablets
50% 101.9 2.1 2.3
100% 100.7 1.5 1.6
150% 98.7 2.5 2.7
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and appropriate technique that could be employed in the 
quality control and stability testing of diltiazem tablets and 
compounded capsules.
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